We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Series A generates impressive $104mm for Adaptimmune
27 Sep 2017
Executive Summary
Adaptimmune Ltd. (developing T-cell therapies for cancer and infectious diseases) closed an oversubscribed Series A financing of $104mm. New Enterprise Associates led and was joined by other first-time backers OrbiMed Advisors, Wellington Management Co., Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Management, Novo AS, QVT, Rock Springs Capital, venBio Select, and Merlin Nexus, along with returning investors including the University of Oxford and others.
Deal Industry
Pharmaceuticals
Biotechnology
Gene Therapy, Cell Therapy
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?